Health
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet
This first-in-human trial shows that a subunit vaccine comprising mammalian cell culture-derived,MF59-adjuvanted, molecular clamp-stabilised recombinant spike protein…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
Privacy Policy Terms and Conditions
-
General23 hours agoTwo British MPs refused entry into Israel, UK foreign ministry says
-
Noosa News23 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General19 hours agoFire razes Tumby Bay hardware store with damage likely to exceed $1m
-
Noosa News3 hours agoExcellence awards nominations received – Proctor